Results 61 to 70 of about 2,570 (187)
2025 Consensus Clinical Management Guidelines for Niemann‐Pick Disease Type C
ABSTRACT In 2018, the International Niemann‐Pick Disease Alliance (INPDA) and the International Niemann‐Pick Disease Registry (INPDR) developed and published comprehensive clinical management guidelines to support inclusive and standardized care pathways in Niemann‐Pick disease type C (NPC)—an ultra‐rare, autosomal recessive, neurovisceral lysosomal ...
Tarekegn Hiwot +33 more
wiley +1 more source
Photocleavable activity-based acid glucosylceramidase probes
Lysosomal acid glucosylceramidase (GBA1) is a lysosomal enzyme that degrades glucolipids with its main substrate being glucosylceramide (GlcCer). Defects in the GBA1 gene lead to glycosphingolipidosis Gaucher disease (GD), in which the hydrolysis of ...
Trenkler, N.E.
core
1-O-acylceramides are natural components of human and mouse epidermis[S]
The lipid-rich stratum corneum functions as a barrier against pathogens and desiccation inter alia by an unbroken meshwork of extracellular lipid lamellae.
Mariona Rabionet +9 more
doaj +1 more source
Preclinical and clinical studies support a strong association between mutations in the GBA1 gene that encodes beta-glucocerebrosidase (GCase) (EC 3.2.1.45; glucosylceramidase beta) and Parkinson's disease (PD).
Alexia Polissidis +9 more
doaj +1 more source
An Australian standard of care for Niemann–Pick disease type C
Abstract Background Niemann–Pick disease type C (NP‐C) is the fifth most prevalent lysosomal disorder in Australia. Diagnostic delay is common, impacted by disease heterogeneity, limited awareness within clinical gateway services and exclusion from state‐based newborn screening programmes.
Michel Tchan +23 more
wiley +1 more source
Health impacts of honey. ABSTRACT Honey is a natural and nutritious product of the honey bee (Apis mellifera) with low water content. Its color ranges from white to amber, with taste varying accordingly. The chemical form and viscosity of honey depend on its composition.
Ecem Bolat +7 more
wiley +1 more source
Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice.
Gaucher disease is caused by an inherited deficiency of the enzyme glucosylceramidase. Due to the lack of a fully functional enzyme there is progressive build-up of the lipid component glucosylceramide. Insufficient glucosylceramidase activity results in
Ehinger, M. +28 more
core +2 more sources
ABSTRACT Background and Aim Parkinson's disease (PD) is primarily known for its motor symptoms but is increasingly recognized for its substantial cognitive effects, particularly on memory. This narrative review aims to clarify the complex molecular mechanisms contributing to memory impairment in PD by integrating findings from both animal and clinical ...
Mohammad Pourfridoni +3 more
wiley +1 more source
The nonlysosomal glucosylceramidase β2 (GBA2) catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. Mutations in the human GBA2 gene have been associated with hereditary spastic paraplegia (HSP), autosomal-recessive cerebellar ataxia ...
Wachten, D. +28 more
core +1 more source
IntroductionThe extensive clinical variations observed in Parkinson's disease (PD) pose challenges in early diagnosis and treatment initiation. However, genetic research in PD has significantly transformed the clinical approach to its treatment. Moreover,
Eun Hye Jeong +4 more
doaj +1 more source

